代谢组学：开放获取

Immunoproteomics Approach for Development of Synthetic Peptide Vaccine from Thioredoxin Glutathione Reductase

Abstract

Somnath Waghmare, Virendra Gomase, Jaywant Dhole and Ramrao Chavan

Schistosomiasis is the second most widespread human parasitic disease. It is principally treated with one drug, praziquantel, which is administered to 100 million people each year; less sensitive strains of schistosomes are emerging. One of the most appealing drug targets against schistosomiasis is thioredoxin glutathione reductase (TGR). This natural chimeric enzyme is a peculiar fusion of a glutaredoxin domain with a thioredoxin selenocysteine (U)-containing reductase domain. Selenocysteine is located on a flexible C-terminal arm that is usually disordered in the available structures of the protein and is essential for the full catalytic activity of TGR. MHC molecules are cell surface proteins, which take active part in host immune reactions and involvement of MHC class in response to almost all antigens and it give effects on specific sites. Predicted MHC binding regions acts like red flags for antigen specific and generate immune response against the parent antigen. So a small fragment of antigen can induce immune response against whole antigen. This theme is implemented in designing subunit and synthetic peptide vaccines. In this study,
we analyzed thioredoxin glutathione reductase of Schistosoma mansoni and is allows potential drug targets to identify active sites, which form antibodies against or infection. The method integrates prediction of peptide MHC class binding; proteosomal C terminal cleavage and TAP transport efficiency. Antigenic epitopes of thioredoxin glutathione reductase are important antigenic determinants against the various toxic reactions and infections.